Affymetrix Launches Cost-Effective Bovine Genotyping Array for Accurate Trait Selection
January 12 2011 - 6:00AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today announced it has launched
the Axiom™ Genome-Wide BOS 1 Array, which has 34 percent higher
genetic coverage than the current leading array because of its
unique design. Developed in conjunction with the Affymetrix Bovine
Consortium of leading breeders and researchers worldwide, the array
comprehensively covers genetic traits from the most commercially
vital breeds of dairy and beef cattle. The Axiom Genome-Wide BOS 1
Array’s high-performing markers greatly improve the reliability of
genetic profiling by giving breeders an accelerated path to higher
quality beef and dairy cattle and reducing the need for costly and
time-consuming phenotypic testing.
Axiom(TM) Genome-Wide BOS 1 Array,
developed in conjunction with the Affymetrix Bovine Consortium of
leading breeders and researchers worldwide, comprehensively covers
genetic traits from the most commercially vital breeds of dairy and
beef cattle. (Photo: Business Wire)
The Affymetrix Bovine Consortium, including the University of
Missouri, U.S. Department of Agriculture’s Agricultural Research
Service (USDA-ARS), Roslin Institute and ARK-Genomics, University
of Edinburgh, Technical University of Munich, and University of
Liverpool, among others, sequenced genomic DNA from a variety of
Bos taurus and Bos indicus breeds, including Holstein, Angus,
Nelore, and Gir, to discover 46 million potential single nucleotide
polymorphisms (SNPs). Approximately 400 samples from 20 diverse
breeds were used to screen millions of these SNPs to identify 3
million high-performing, validated polymorphic SNPs. Finally, a
subset of more than 648,000 SNPs was selected using a novel array
design process that maximizes genetic coverage and minimizes
redundancy for cost-effective genotyping.
“We're proud to be a part of a highly successful collaboration
and that our new genetic profiling application will generate
enormous value for breeders in terms of expense and time savings,”
said Kevin King, Affymetrix President and CEO. “We’re hearing from
our collaborators that our array is setting a new standard for
cattle genotyping because it supplies what other options
lack—maximum genetic coverage for an affordable price.”
Three million validated SNPs comprise the newly launched Axiom
Bovine Genomic Database, which has supplied many Affymetrix Bovine
Consortium members with data obtained from their samples. Now, the
database is available to all breeders and researchers who also want
to design their own customized arrays through the Axiom myDesign™
Genotyping Array service.
Neogen Corporation’s (NASDAQ:NEOG) subsidiary GeneSeek®, a
global provider of DNA testing for farm animal improvement and
veterinary diagnostic testing and surveillance, will be among the
first to offer Axiom Genotyping Solution services to the bovine
community using the GeneTitan® System.
“Since 1998, GeneSeek has been providing comprehensive solutions
and services for the agricultural biotechnology industry,” said
Andy Last, Chief Commercial Officer at Affymetrix. “We are excited
to see GeneSeek evaluating our platform to better serve its
worldwide customers who are increasingly seeing the importance of
using genotyping in their breeding process.”
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,000 systems have been shipped around the world and more than
22,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 1,000 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit
http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies” or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2009, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, Axiom MyDesign and
GeneTitan System are trademarks or registered trademarks of
Affymetrix Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6570424&lang=en
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024
